Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer

Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer

Background: Immunotherapy with programmed death receptor-1 (PD-1) inhibitors, as a single agent or in combination with chemotherapy, is the standard first-line treatment for recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC). Unfortunately, there is no established second-line tre...

Full description

Bibliographic Details
Main Authors: Kimberly M. Burcher, Chance H. Bloomer, Elena Gavrila, John M. Kalada, Mark J. Chang, Rediet R. Gebeyehu, Alexander H. Song, Lara M. Khoury, Thomas W. Lycan, Rebecca Kinney, Ralph D’Agostino, Paul M. Bunch, Kirtikar Shukla, Pierre Triozzi, Cristina M. Furdui, Wei Zhang, Mercedes Porosnicu
Format: Article
Language:English
Published: SAGE Publishing 2024-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231217959

Internet

https://doi.org/10.1177/17588359231217959

Similar Items